Aktis Oncology, Inc. Common stock

Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.

Biotech & Genomic Medicine▲

Novartis, Lilly, Bristol Myers Eye Aktis Oncology Takeover

Aktis Oncology, a clinical-stage radiopharmaceutical company, is seen as a potential acquisition target for Novartis, Eli Lilly, and Bristol Myers Squibb due to its alpha-emitting cancer platform and upcoming trial data. Aktis retains full worldwide rights to its miniprotein radioconjugate platform, with $517.3 million in cash and preliminary data from its lead candidate AKY-1189 expected in the first quarter of 2027. Novartis, whose Pluvicto grew 43% in Q2 2026, and Eli Lilly, already a $60 million upfront partner, rank as the top two strategic acquirers. Analysts target $34.42 for AKTS while the 24/7 Wall St. base case reaches $42.16, but a failed readout would erase the takeout premium entirely.

AKTS ▲NOVN.SW ▲BMY LLY

Biotech & Genomic Medicine

24/7 Wall St.·7dRead more ▾